WaferGen Bio-systems Announces a Commercial Partnership with a Major Molecular Diagnostic Laboratory

FREMONT, Calif., July 31, 2014 /PRNewswire via COMTEX/ WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today a commercial partnership with Molecular Pathology Laboratory Network, Inc. (MPLN) with the goal of developing Next-Generation sequencing (NGS) based clinical tests. One of the key challenges in developing clinical grade targeted NGS panels is achieving complete coverage of the required genes. Based on my experience, WaferGen s target enrichment technology offers a unique solution that not only provides adequate coverage, but also reduces the number of steps in sample preparation. We feel that this is ideal for our clinical lab setting, stated Dr. Jamie Platt, Vice President of Genomic Solutions at MPLN. The first product to be commercialized through this commercial partnership is a solid tumor panel to complement MPLN s Pathology Partners Program and support the expanding Molecular Oncology Services menu, added Dr. Platt. Partnership with MPLN is the latest example of the ad
http://bit.ly/1AD2g2m